Skip to content

    Rainbow Child.

    RAINBOWGood
    Healthcare·10 Feb 2025
    Management Summary

    Rainbow Children's Medicare delivered a strong Q3 FY25 performance with double-digit growth across revenue and profitability, despite seasonal variations and international business challenges. The company is aggressively pursuing a hub-and-spoke expansion strategy, targeting 1,000 additional beds in the next 3.5 years, primarily through internal accruals. While international medical tourism saw a sharp decline due to geopolitical tensions, domestic demand and the ramp-up of new facilities in Hyderabad, Bangalore, and Chennai continue to drive momentum.

    Highlights

    8
    • Revenue grew 18.5% YoY to ₹398 crores, driven by 12% growth in both IP and OP volumes.

    • EBITDA increased 14% YoY to ₹134.3 crores with a healthy margin of 33.8%.

    • PAT registered a growth of 10.2% YoY, reaching ₹68.9 crores.

    • Overall occupancy stood at 53.2%, with mature hospitals at 60.2% and new hospitals at 39.6%.

    • Management announced a target to add ~1,000 beds over the next 3.5 years.

    • International business faced significant headwinds, declining 40% YoY due to geopolitical issues in key regions.

    • Average Revenue Per Patient (ARPP) growth remained consistent between 5% to 8%.

    • Net cash position remains robust at ₹667 crores as of December 31, 2024.

    Concerns

    1
    • International Business Headwinds

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹398 Cr+18.5%YoY
    2. 02EBITDA₹134.3 Cr+14.0%YoY
    3. 03EBITDA Margin33.8%
    4. 04PAT₹68.9 Cr+10.2%YoY
    5. 05Occupancy Rate53.2%

    Segment breakdown

    Mature Hospitals
    60.2% Occupancy Rate9% IP Volume Growth
    New Hospitals
    39.6% Occupancy Rate₹8.5 Cr EBITDA Drag (9M)
    International Business
    2% Revenue Contribution-40% Revenue Decline
    List

    Guidance & targets

    5
    CategoryTargetPriority
    Capacity
    Total Bed Additions
    1,000 beds
    High
    Capacity
    New Bed Additions FY26
    250 beds
    High
    Capex
    Gurugram Project Capex
    ₹400 crores
    Medium
    Margin
    EBITDA Margin Band
    31.7% - 33.7%
    Medium
    Revenue
    International Business Revenue
    ₹34 crores
    Medium

    Risks & concerns

    4
    RiskSeverity

    International Business Headwinds

    Geopolitical issues in Bangladesh, Somalia, Sudan, and Oman have led to a 40% decline in medical tourism revenue.Management acknowledged

    high

    Increased Average Length of Stay (ALOS)

    ALOS increased by 12% due to operational delays in insurance approvals and higher case complexity, suppressing ARPOB.Both acknowledged

    medium

    Project Delays

    Slight delays in Coimbatore and Rajahmundry due to regulatory redesigns and vendor locations in Tier 2 cities.Management acknowledged

    low

    Areas of Evasion(1)

    • Specific outlook for FY26 occupancy and ARPOB was deferred to the next call.

    Q&A highlights

    3

    “ARPOB is a somewhat complex subject because it has two key variables: Seasonality and ALOS. If ALOS increases, ARPOB gets suppressed... That’s why we are guiding and requesting all analysts and investors to focus on our ARPP growth instead.”

    Clarifies that management views Average Revenue Per Patient (ARPP) as a more reliable indicator of pricing power and case complexity than ARPOB, which is distorted by length of stay.

    asked by Alankar Garude, Kotak Institutional Equities

    2 min read5 chapters

    Detailed Narrative

    01

    Robust Domestic Growth Offsets International Headwinds

    Rainbow reported a strong 18.5% YoY revenue growth for Q3 FY25, reaching ₹398 crores. This was underpinned by a 12% increase in both inpatient and outpatient volumes. While the international business segment saw a sharp 40% decline due to geopolitical instability in regions like Bangladesh and Somalia, the domestic business remained resilient. Management has revised the FY25 international revenue target down to ₹34 crores from ₹44 crores last year, but remains optimistic about long-term medical tourism potential once new markets like the Philippines and Uganda are explored.

    02

    Aggressive Capacity Expansion Roadmap

    The company is on track to add approximately 1,000 beds over the next 3.5 years. In FY26 alone, Rainbow plans to add 250 beds across three new hospitals, which are expected to be asset-light leased facilities with a capex of ₹60-65 lakh per bed. The Rajahmundry hub (100 beds) is nearing completion for a May 2025 launch, while spoke hospitals in Electronic City and Hennur are slated for Q2 FY26. This expansion is expected to drive a 12.5% to 13% capacity increase in the next financial year.

    03

    Strategic Shift in NCR: The Gurugram Project

    Rainbow is transitioning to an asset-heavy model for its entry into the Delhi-NCR region. The Gurugram project involves two land parcels in Sectors 56 and 44, with construction expected to start in 4-6 weeks. The company has already invested ₹180-190 crores in land and expects to spend another ₹400 crores over the next three years. This results in a significantly higher capex of ₹1.5 crores per bed, which management justifies as necessary for a state-of-the-art super-specialty facility aimed at serving North India and international patients.

    04

    Operational Metrics: Focus on ARPP over ARPOB

    Management highlighted a shift in internal focus from ARPOB to Average Revenue Per Patient (ARPP) due to the volatility of Average Length of Stay (ALOS). ALOS increased by 12% this quarter, partly due to insurance approval delays and higher case complexity, which naturally suppresses ARPOB. ARPP has shown consistent growth of 5% to 8%, reflecting better pricing power and a shift toward more complex clinical cases. Mature hospitals continue to maintain healthy occupancy levels above 60%, with a theoretical peak identified at 68-70%.

    05

    Margin Resilience Amidst Expansion Drag

    Despite the inherent drag from three new hospitals launched in early 2024, Rainbow maintained a strong EBITDA margin of 33.8% in Q3. The EBITDA drag from new units was approximately ₹8-9 crores for the first nine months of FY25. Management guided for a stable EBITDA margin band within +/- 1% of the current 32.7% level as they balance the ramp-up of existing new units with the initial costs of upcoming facilities. One-off📎 expenses of ₹7 crores related to silver jubilee celebrations also impacted 9M margins slightly.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.